Infliximab
Medicare fails to ‘keep up with’ Medicaid, private market on infliximab biosimilar uptake
SAN DIEGO — Compared with Medicaid and private insurance, Medicare has lagged significantly in adopting infliximab biosimilars despite the multiple options now available, according to data presented at ACR Convergence 2023.
FDA grants de novo status to ‘5-minute’ drug monitoring tests for Humira, Remicade in IBD
The FDA has granted de novo clearance to ProciseDx Inc. for its therapeutic drug monitoring tests for Humira and Remicade, as well as their biosimilars, in patients with inflammatory bowel disease, according to a company release.
Infliximab may improve visual acuity in PVR associated with RRD
SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an intravitreal injection of infliximab after pars plana vitrectomy, according to a study.
Children with Cogan’s syndrome should undergo infectious disease screening, brain MRI
Children with Cogan’s syndrome should undergo thorough evaluations upon presentation, including screenings for autoimmune and infectious diseases, as well as echocardiography and brain MRI, according to data.
Infliximab effective as adjunctive therapy for patients with central nervous system TB
Infliximab was found to be safe and effective as adjunctive therapy for patients with central nervous system tuberculosis, researchers reported.
RheumMadness combines brackets, peer-teaching to find most impactful paper ‘ever written’
What concept represents the most important and transformational article ever written in all of rheumatology?
More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13
CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.
Ileocecal resection may have role as ‘primary treatment’ in recently diagnosed Crohn’s
CHICAGO — Patients who underwent ileocecal resection for Crohn’s disease had a 33% lower risk for hospitalization, repeat surgery, systemic corticosteroid exposure and perianal CD, according to a presenter at Digestive Disease Week.
Adalimumab plus methotrexate lowers treatment failure 2-fold in pediatric Crohn’s
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.
Subcutaneous infliximab could ‘transform’ how patients with IBD navigate care
Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.